The Evolution of Treatment Options in Renal Cell Carcinoma

Eric Jonasch, MD


January 28, 2022

Eric Jonasch, MD, discusses the evolution of treatment options for patients with renal cell carcinoma (RCC) that he has witnessed during his career. From the first RCC patients that he treated with cytokine therapies, to the revolution of tyrosine kinase inhibitors and immunotherapy combinations, Dr Jonasch believes that we are now at the point in this evolution where there is potential that a subset of patients can be cured, something he could not have believed at the start of his journey.


Comments on Medscape are moderated and should be professional in tone and on topic. You must declare any conflicts of interest related to your comments and responses. Please see our Commenting Guide for further information. We reserve the right to remove posts at our sole discretion.